Christopher Waddick
Directeur Financier/CFO chez CARDIOL THERAPEUTICS INC.
Fortune : 202 400 $ au 30/04/2024
Postes actifs de Christopher Waddick
Sociétés | Poste | Début | Fin |
---|---|---|---|
CARDIOL THERAPEUTICS INC. | Directeur/Membre du Conseil | 19/05/2022 | - |
Directeur Financier/CFO | 16/08/2018 | - | |
Secrétaire Général | 16/08/2018 | - | |
Active Energy, Inc.
Active Energy, Inc. Electric UtilitiesUtilities Active Energy, Inc. operates as an energy management firm. It offers energy assessment, electricity products and services, natural gas products and services, and cap and trade. The company is headquartered in Burlington, Canada. | Directeur Financier/CFO | 01/01/2013 | - |
President | 01/01/2013 | - | |
Nrj Consulting, Inc. | President | 01/11/2009 | - |
Historique de carrière de Christopher Waddick
Anciens postes connus de Christopher Waddick
Sociétés | Poste | Début | Fin |
---|---|---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Directeur Général | - | - |
Directeur des opérations | 01/07/2005 | 01/06/2007 | |
Directeur Financier/CFO | 01/06/2007 | 23/10/2009 |
Formation de Christopher Waddick
York University | Masters Business Admin |
Wilfrid Laurier University | Undergraduate Degree |
Statistiques
Internationale
Canada | 6 |
Etats-Unis | 2 |
Opérationnelle
Director of Finance/CFO | 3 |
President | 2 |
Chief Executive Officer | 1 |
Sectorielle
Health Technology | 3 |
Consumer Services | 3 |
Utilities | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
CARDIOL THERAPEUTICS INC. | Health Technology |
Entreprise privées | 3 |
---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Health Technology |
Active Energy, Inc.
Active Energy, Inc. Electric UtilitiesUtilities Active Energy, Inc. operates as an energy management firm. It offers energy assessment, electricity products and services, natural gas products and services, and cap and trade. The company is headquartered in Burlington, Canada. | Utilities |
Nrj Consulting, Inc. |
- Bourse
- Insiders
- Christopher Waddick
- Expérience